Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Department of Internal Medicine, Poznań University of Medical Sciences, 60-780 Poznan, Poland.
Int J Mol Sci. 2024 Mar 31;25(7):3901. doi: 10.3390/ijms25073901.
Cardiovascular diseases (CVDs) are the leading cause of death and include several vascular and cardiac disorders, such as atherosclerosis, coronary artery disease, cardiomyopathies, and heart failure. Multiple treatment strategies exist for CVDs, but there is a need for regenerative treatment of damaged heart. Stem cells are a broad variety of cells with a great differentiation potential that have regenerative and immunomodulatory properties. Multiple studies have evaluated the efficacy of stem cells in CVDs, such as mesenchymal stem cells and induced pluripotent stem cell-derived cardiomyocytes. These studies have demonstrated that stem cells can improve the left ventricle ejection fraction, reduce fibrosis, and decrease infarct size. Other studies have investigated potential methods to improve the survival, engraftment, and functionality of stem cells in the treatment of CVDs. The aim of the present review is to summarize the current evidence on the role of stem cells in the treatment of CVDs, and how to improve their efficacy.
心血管疾病(CVDs)是死亡的主要原因,包括多种血管和心脏疾病,如动脉粥样硬化、冠状动脉疾病、心肌病和心力衰竭。CVDs 有多种治疗策略,但需要对受损心脏进行再生治疗。干细胞是具有广泛分化潜能的多种细胞,具有再生和免疫调节特性。多项研究评估了干细胞在 CVDs 中的疗效,如间充质干细胞和诱导多能干细胞衍生的心肌细胞。这些研究表明,干细胞可以改善左心室射血分数、减少纤维化和减小梗塞面积。其他研究还探讨了改善 CVDs 治疗中干细胞的存活、植入和功能的潜在方法。本综述的目的是总结干细胞在 CVDs 治疗中的作用以及如何提高其疗效的现有证据。
Int J Mol Sci. 2024-3-31
Curr Drug Targets. 2019
Curr Stem Cell Res Ther. 2020
Rev Cardiovasc Med. 2025-7-22
Essays Biochem. 2025-3-25
Rev Cardiovasc Med. 2025-2-21
Int J Mol Sci. 2024-11-1
Circulation. 2024-4-30
J Biomed Mater Res A. 2024-4
Front Cardiovasc Med. 2023-12-6